title: Psoralidin inhibits proliferation and enhances apoptosis of human esophageal carcinoma cells via NF-κB and PI3K/Akt signaling pathways.
abstract: Esophageal cancer is the most common gastrointestinal cancer. Psoralidin exhibits antioxidant, anti-apoptotic, anti-inflammatory and antitumor effects, which result in the inhibition of cancer formation. The present study aimed to investigate the effect of psoralidin on esophageal carcinoma proliferation and growth, and to elucidate its underlying mechanism of action. The effect of psoralidin on cell proliferation was investigated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Using an annexin V-fluorescein isothiocyanate/propidium iodide apoptosis detection kit and 4',6-diamidino-2-phenylindole staining assay, the present study demonstrated that psoralidin significantly enhanced apoptosis of human esophageal carcinoma Eca9706 cells. In addition, caspase-3 activity was analyzed with a caspase-3 colorimetric assay kit, while nuclear factor (NF)-κB activity and protein phosphatidylinositol 3-kinase (PI3K)/Akt expression were measured with an NF-κB enzyme-linked immunosorbent assay kit and western blot analysis, respectively. Eca9706 cells were treated with a PI3K agonist in order to investigate the mechanism of action of psoralidin. It was observed that psoralidin was able to decrease the proliferation and promote the cellular apoptosis of Eca9706 cells in a dose-dependent manner. Furthermore, psoralidin was also able to inhibit the caspase-3 activity of Eca9706 cells in a dose-dependent manner. In addition, psoralidin inhibited NF-κB activity and reduced PI3K and Akt protein expression in Eca9706 cells. Notably, the PI3K agonist was able to reverse the effect of psoralidin on Eca9706 cells. The results of the present study demonstrated that psoralidin was able to inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells via the NF-κB and PI3K/Akt signaling pathways.
authors.affiliation: Department of Oncology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China.
authors.forename: Zhiliang
authors.initials: Z
authors.lastname: Jin
authors.affiliation: Department of Gastroenterology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China.
authors.forename: Wei
authors.initials: W
authors.lastname: Yan
authors.affiliation: Department of Neonatology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China.
authors.forename: Hui
authors.initials: H
authors.lastname: Jin
authors.affiliation: Department of Oncology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China.
authors.forename: Changzheng
authors.initials: C
authors.lastname: Ge
authors.affiliation: Department of Oncology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China.
authors.forename: Yanhua
authors.initials: Y
authors.lastname: Xu
keywords: Akt; NF-κB; PI3K; esophageal cancer; psoralidin